Oct 3 (Reuters) - Chinese biotech companies WuXi AppTec
and WuXi Biologics , which are being targeted by a forthcoming U.S. national security legislation, are working on sales of some of their operations, the Financial Times reported on Thursday, citing people familiar with the matter.
WuXi AppTec has put its cell and gene therapy manufacturing arm WuXi Advanced Therapies, which operates four laboratories and manufacturing facilities in Philadelphia, up for sale, the newspaper reported.
WuXi Biologics is also working with advisers to test interest in some of its European production facilities, FT reported, citing three people familiar with the situation.
(Reporting by Rishabh Jaiswal in Bengaluru; Editing by Sonia Cheema)
((rishabh.jaiswal@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。